Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

27.05.2014

Zurich, Switzerland, May 27th, 2014 and Osaka, Japan, May 28th, 2014 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio® (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.1 UC and CD are the two most common types of inflammatory bowel disease (IBD),2 affecting more than four million people worldwide,3,4,5,6,7,8 including approximately 2.2 million in Europe.5...

Read more

 

Top of page

Takeda Pharma